Clinical trials: Thymus Cancer
Thymoma and Thymic Carcinoma
Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors
This study is designed to evaluate the feasibility and safety of concurrent chemoradiotherapy for limited advanced unresectable thymoma or thymic carcinoma.
- Trial name
- NCT02636556
- Testing
- concurrent chemoradiation
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Fudan University
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
NSCLC, Mesothelioma
Folinic Acid for Prevention of Pemetrexed-induced Toxicity
Objective The main objective is to evaluate the haematological toxicity in patients who use pemetrexed with and without rescue therapy with folinic acid.
- Conditions
- NSCLC, Mesothelioma, Thymoma
- Trial name
- FLEX (NCT06010277)
- Testing
- Folinic acid
- Where
- 2 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- Amphia Hospital
Esophageal Neoplasms, Lung Neoplasms
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Background: Mithramycin is a new cancer drug. In another study, people with chest cancer took the drug 6 hours a day for 7 straight days. Many of them had liver damage as a side effect.
- Conditions
- Esophageal Neoplasms, Lung Neoplasms, Mesothelioma, Thymus Neoplasms
- Trial name
- NCT02859415
- Testing
- Mithramycin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Carbon Ion Radiotherapy, Thymoma, Thymic Carcinoma, Radiotherapy, Chemotherapy
Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced (all visible lesions can be included in the radiation target area in this treatment)…
- Trial name
- NCT06186726
- Testing
- carbon ion radiotherapy
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Jian Chen
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thymoma
Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours
The purpose of this study is to determine whether radiotherapy (RT) combined with recombined human granulocyte-macrophage colony stimulating factor(rhGM-CSF) is safe, effective in the treatment of patients with advanced thymic…
- Trial name
- NCT05407649
- Testing
- Radiotherapy Combined with GM-CSF
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Cancer Hospital, China
Thymic Carcinoma, Non-small Cell Lung Cancer
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
This is a two-agent, open-label, non-randomized, Phase 1/2 dose escalation and dose expansion study of combinatorial oral vorolanib plus infusional nivolumab in patients with Non-Small Cell Lung Cancer naïve to checkpoint…
- Conditions
- Thymic Carcinoma, Non-small Cell Lung Cancer, Refractory Thoracic Tumors, Small-Cell Lung Cancer
- Trial name
- NCT03583086
- Testing
- Vorolanib, Nivolumab
- Where
- 7 sites in United States
- Volunteers
- 88 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Thymic Carcinoma
Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma
This study is important to demonstrate if single agent activity is noted for patients with thymic tumors over expressing c-kit and/or PDGF.
- Trial name
- NCT00314873
- Testing
- Gleevec (imatinib)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Indiana University
Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma
Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well carboplatin and paclitaxel with or without ramucirumab work in treating patients with thymic cancer that has spread to other places in the body, has come back, or cannot be removed…
- Conditions
- Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Recurrent Thymic Carcinoma, Unresectable Thymic Carcinoma
- Trial name
- NCT03694002
- Testing
- Carboplatin, Paclitaxel, Ramucirumab
- Where
- 254 sites in United States
- Volunteers
- 21 people
- Sponsor
- SWOG Cancer Research Network
Type B3 Thymoma, Thymic Carcinoma
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
Study to investigate response to sunitinib in patients with thymic epithelial tumours who had progressive disease after at least one previous regimen of platinum-based chemotherapy.
- Trial name
- Style (NCT03449173)
- Testing
- Sunitinib
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Carcinoma
Survival Nomogram for Patients With Thymic Carcinoma
Background Thymic carcinoma (TC) is a rare and aggressive mediastinal malignancy with poor prognosis. Our study aimed to develop a nomogram to predict overall survival (OS) of TC patients.
- Trial name
- NCT07179341
- Testing
- Thymectomy for thymic carcinoma
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Weijie Ye
Thymic Carcinoma
Sacituzumab Tirumotecan in Participants With Locally Advanced or Metastatic Thymic Carcinoma
The goal of this clinical trial is to learn if drug Sac-TMT works to treat Thymic Carcinoma. It will also learn about the safety of Sac-TMT.
- Trial name
- NCT07324629
- Testing
- Sacituzumab tirumotecan
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Thymoma, Thymic Carcinoma
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010257
- Testing
- carboplatin, paclitaxel
- Where
- 67 sites in United States
- Volunteers
- 46 people
- Sponsor
- Eastern Cooperative Oncology Group
Thymoma, Thymus Neoplasms
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Background: Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers. However, it has not been approved to treat cancers of the thymus.
- Trial name
- NCT01621568
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Malignancy, Cancer
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide…
- Conditions
- Malignancy, Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT01242072
- Testing
- palifosfamide-tris
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Alaunos Therapeutics
Thymic Cancer
A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor
This is a phase II single center, open-label, single arm study of palbociclib treatment in patients with recurrent or metastatic advanced TETs after failure of one or more cytotoxic chemotherapy regimens.
- Trial name
- NCT03219554
- Testing
- Palbociclib
- Where
- South Korea
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.
This study for a single-center prospective phase II randomized controlled train to assess the efficacy and safety of Induction therapy on thymoma .Methods patients with thymoma (stage Ⅲ and stage Ⅳa) were treated with 2 cycles of…
- Trial name
- NCT05816694
- Testing
- NAB-Paclitaxel plus Cisplatin, Cisplatin plus Epirubicin plus Cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peng Liu